A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance
Status:
Recruiting
Trial end date:
2023-10-06
Target enrollment:
Participant gender:
Summary
Study researchers think that a drug called enasidenib may help people with clonal cytopenia
of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which
may improve blood cell counts. The purpose of this study is to find out whether enasidenib is
a safe and effective treatment for CCUS.